Mesenchymal stem cells explained: why MSCs anchor regenerative programmes

MSCs are named for their ability to become connective-tissue cells such as bone, cartilage and fat, but in modern clinical practice most interest lies not in differentiation but in what the cells secrete.

MSC secretions include signalling proteins and exosome vesicles affecting inflammation, new blood vessel formation and neighbouring cell behaviour — collectively called paracrine effects.

Different sources have different properties: adipose yields large numbers via a minor procedure, bone marrow has the longest clinical track record, and umbilical tissue is described as having high expansion potential because it comes from neonatal tissue.

Legally, autologous and donor-derived cells fall under different rules in each country. Ask clearly which your plan uses and how it sits within Korean regulation.

A limitation: MSC quality and quantity decline with age and health status, which is why clinics emphasise harvest timing and addressing fundamentals first.

Finally, MSC research remains in development for many indications; claims should rest on evidence for the relevant indication rather than a blanket assertion of universal benefit.